

alkaloids, and is currently one of the most active agents for the treatment of non-small cell lung cancer (NSCLC) or other solid tumors [2–4].

Vinorelbine is most commonly administered through a peripheral vein as drip infusion over a period of between 6 and 10 min [5]. However, vinorelbine is a moderate vesicant that is well documented to cause local venous toxicity such as drug induced-phlebitis and venous irritation, and its incidence of approximately 30% has been reported in patients who received vinorelbine via a 6–10 min drip infusion [6,7]. Although local venous toxicity is not life threatening, it can result in discomfort or pain and can be a disincentive of chemotherapy to the patients. Therefore local venous toxicity should be managed effectively to decrease patient discomfort.

Recently, a retrospective study on drug induced-phlebitis with bolus injection of vinorelbine has been reported. In the analysis of 39 patients who received the administration of bolus injection of vinorelbine, drug induced-phlebitis occurred in only 1 of 39 patients (2.6%). The results suggested that the administration of bolus injection of vinorelbine might decrease the incidence of drug induced-phlebitis when compared common drip infusion [8]. Furthermore, shortening the infusion time of vinorelbine has also been reported to reduce the incidence of drug induced-phlebitis [9], although a randomized trial evaluating the bolus injection of vinorelbine has not been performed.

We conducted a prospective randomized trial to determine whether a 1-min bolus injection (1 min bolus) of vinorelbine reduced the incidence of local venous toxicity compared with a 6-min drip infusion (6 min infusion). In addition, we assessed the incidence of acute lower back pain, which has been reported to occur in shorter time infusions of vinorelbine [10] as other toxicity.

2. Patients and methods

2.1. Patient eligibility

Patients who had histological or cytological evidence of cancer, and planned to receive vinorelbine-containing chemotherapy as peripheral infusion, were eligible for this study. The patients were required to be 20 years of age or older and have an Eastern Cooperative Oncology Group performance status (PS) of 0–2. Patients were excluded if they had previous treatment with vinorelbine, medical condition that required regular use of steroids, or were pregnant or nursing. All patients provided written informed consent before randomization for this study, and the study was approved by the institutional review board at the National Cancer Center.

2.2. Study design

This study was a randomized trial comparing 1 min bolus of vinorelbine with 6 min infusion for the control of local venous toxicity. The study was performed in the National Cancer Center Hospital East. Patients were randomly assigned to receive either 6 min infusion or 1 min bolus by a minimization method. Before randomization, patients were stratified by chemotherapy regimens (stra-

tum I: vinorelbine plus cisplatin, stratum II: vinorelbine plus gemcitabine, stratum III: vinorelbine alone) and body mass index (BMI) (stratum I: normal (BMI < 24), stratum II: high (BMI 24 or more)). We reported previously that high BMI was associated with a significant increased risk of vinorelbine irritation [6].

2.3. Treatment plan

Patients received either 6 min infusion or 1 min bolus of vinorelbine. Vinorelbine was diluted in 50 ml (6 min infusion) or 20 ml (1 min bolus) normal saline, respectively. All infusions were administered through a peripheral vein and followed by flushing the vein with approximately 200 ml of fluid. The administration of other drugs for the prevention of local venous toxicity was not allowed. Vinorelbine-containing chemotherapy regimens consisted of vinorelbine 20–25 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 1 every 3 weeks, vinorelbine 20–25 mg/m² plus gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks, or vinorelbine 20–25 mg/m² alone on days 1, 8 and 15 every 4 weeks.

2.4. Outcome assessment

The primary endpoint of this study was the incidence of local venous toxicity per patient. Local venous toxicity was evaluated at each infusion up to two cycles and graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0 for injection site reaction by attending physician: grade 0, none; grade 1, pain, itching or erythema; grade 2, pain or swelling, with inflammation or phlebitis; and grade 3, ulceration or necrosis that is severe or prolonged or requires surgery. After the administration of vinorelbine, patients self-recorded in personal dairies symptoms of pain, itching, swelling, blister, or ulceration at injection. The patient's dairies were also used for support of diagnosis of local venous toxicity. Local venous toxicity was categorized as positive or negative, with positive defined as experience of grade 1 or more local venous toxicity at least once during treatment. The secondary endpoint of this study was the incidence of local venous toxicity per infusions and other toxicity. The incidence of acute lower back pain, which was reported to occur in shorter time infusion of vinorelbine, and hematological toxicity were mainly assessed as the other toxicity, and graded according to NCI-CTC version 2.0.

2.5. Statistical analysis

The purpose of this study was to determine whether 1 min bolus of vinorelbine reduced the incidence of local venous toxicity compared with 6 min infusion. The calculation of sample size was based on the estimated incidence of local venous toxicity per patient in the two treatment groups. On the basis of previous reports [6,8], an incidence of local venous toxicity per patients of 30% in 6 min infusion and of 5% in 1 min bolus was assumed. To demonstrate this hypothesis with an alpha of 5% and a power of 80% in a two-sided test, thirty-five patients from each group were required. A total of 80 patients were projected to be accrued. All comparisons between proportions were performed by the Chi-square test

or Fisher's exact test, as appropriate. Multivariate analysis was performed by logistic regression procedure to determine the relationship between the incidence of local venous toxicity and the clinical variables. *P* values < 0.05 were considered significant. The reported *P* values were based on two-sided tests. Statistical analysis software (StatView-J Ver.5.0, Macintosh) was used for the analyses.

3. Results

3.1. Patient characteristics

Between October 2002 and April 2003, 83 patients were enrolled and randomly assigned into the study. Baseline patient characteristics according to treatment group are shown in Table 1. The two treatment groups were well balanced in regards to age, PS, chemotherapy regimens, and BMI. All patients had advanced NSCLC and no prior chemotherapy. Two patients were not assessable for analysis because they refused to receive chemotherapy after randomization.

Treatment delivery is shown in Table 2. One hundred and thirty-eight infusions to 40 patients in 6 min infusion and 135 infusions to 41 patients in 1 min bolus were delivered. There was no significant difference between the two arms for treatment delivery of vinorelbine.

3.2. The incidence of local venous toxicity

The incidence of local venous toxicity was 33% (95% confidence interval (CI), 18.6–49.1%) in 6 min infusion (13 of the 40 patients) and 24% (95% CI, 12.4–40.3%) in 1 min bolus (10 of the 41 patients) (Fig. 1a). There was no statistically

Table 2 Treatment delivery

	6 min drip infusion	1 min bolus injection
Evaluable patients	40	41
Vinorelbine infusions		
1	1	3
2	9	8
3	1	4
4	29	26
Total infusions	138	135
Vinorelbine (mg)/body		
Median (range)	39 (30–48)	40 (27–48)

significant difference between the two arms (*P*=0.41; relative risk, 0.67; 95% CI, 0.25–1.77). In 6 min infusion, grade 1 local venous toxicity was observed in 12 patients, grade 2 in 1 patient; in 1 min bolus, grade 1 local venous toxicity was observed in 8 patients, grade 2 in 2 patients. No severe local venous toxicity was seen with both arms. The incidence of local venous toxicity per infusions was 16% in 6 min infusion (22 of 138 infusions) and 11% in 1 min bolus (15 of 135 infusions) (*P*=0.47) (Fig. 1b).

The incidence of local venous toxicity according to chemotherapy regimens were 29% (18/60) in the vinorelbine plus cisplatin group, 22% (2/9) in the vinorelbine plus gemcitabine group, and 25% (1/4) in the vinorelbine alone group, respectively. The incidence of local venous toxicity in the normal BMI group was 30% compared with 24% in the high BMI group (*P*=0.77). There was no statistically significant difference among the stratified factors. We used multivariate logistic regression analysis to determine the relationship

Table 1 Baseline patients characteristics

Characteristic	6 min drip infusion (n=41)		1 min bolus injection (n=42)		<i>P</i>
	No.	%	No.	%	
Age (years)					
Median	65		65		0.37
Range	42–76		49–78		
Sex					
Male	29	71	36	86	0.10
Female	12	29	6	14	
ECOG performance status					
0/1	7/29	88	11/28	93	0.48
2	5	12	3	7	
Chemotherapy regimen					
Vinorelbine/cisplatin	35	85	35	83	0.95
Vinorelbine/gemcitabine	4	10	5	12	
Vinorelbine alone	2	5	2	5	
Body mass index					
Median (range)		21.7 (13.5–34.2)		21.2 (14.7–29.9)	0.79
Normal ≤ 24	31	76	31	74	
High > 24	10	24	11	26	

ECOG, Eastern Cooperative Oncology Group.




Fig. 1 The incidence of local venous toxicity: (a) per patient, (b) per infusions.

between local venous toxicity and the clinical variables (sex, age, chemotherapeutic regimen, BMI, the dose of VNR, and treatment arm). No significant correlations between the incidence of local venous toxicity and the clinical variables were found.

According to the patient's self-recorded diary, 43% (17/40) of patients in 6 min infusion had at least one symptom at injection site and 34% (14/41) of patients in 1 min bolus ($P=0.43$).

3.3. Other toxicity

Acute lower back pain (>grade 1) was observed in 8% of 6 min infusion, and in 7% of 1 min bolus. There was no statistically significant difference between the two arms ($P>0.99$). Grade 3/4 neutropenia and thrombocytopenia occurred with similar frequency in both arms.

4. Discussion

Local venous toxicity such as drug induced-phlebitis is one of the discomforting toxicities for patients in cancer chemotherapy. Vinorelbine is generally well tolerated and can be administered safely in an outpatient setting; however, it is a moderate vesicant with the potential to cause local venous toxicity. In our study, the incidence of local venous toxicity with the 6-min drip infusion of vinorelbine, which was used as control arm, was 33%, a similar frequency as found in past reports [6,7].

This is the first randomized study that evaluated the incidence of local venous toxicity with the bolus injection of vinorelbine. In this study, the administration of 1 min bolus of vinorelbine did not significantly reduce the incidence of local venous toxicity compared with 6 min infusion. The 24% rate of local venous toxicity with 1 min bolus of vinorelbine, which was observed in our study, was higher than anticipated in the study hypothesis. We speculate that our study hypothesis overestimated the incidence of local venous toxicity with 1 min bolus of vinorelbine because the previous reference reports were not prospective randomized studies [7,8]. Indeed, our study indicated that the administration of 1 min bolus of vinorelbine resulted in a non-statistically significant 27% reduction in rate of local venous toxicity compared with the 33% rate of 6 min infusion. We think that our

study might have no under power to detect a clinically significant difference between the two treatment groups. In our study, an overall incidence of local venous toxicity was 28% although no severe local venous toxicity was seen. If a patient with only poor peripheral venous access receives the administration of vinorelbine, the use of implantable central venous access device should be considered. Moreover, the administration of 1 min bolus of vinorelbine has not been associated with an increased risk of acute lower back pain, which was previously reported to occur in shorter time infusions of vinorelbine [10]. Hematologic toxicity such as neutropenia and thrombocytopenia were also equivalent in both arms. In addition, we examined the clinical risk factors related to local venous toxicity of vinorelbine, but unfortunately there was no significant clinical risk factor in this study.

Two other randomized studies have been performed for the control of local venous toxicity of vinorelbine. Lazano et al. [9] compared the use of heparin-containing solution as anti-thrombotic effect [11] with 10-min infusion of vinorelbine. In their study, a population of 23 patients was randomized to arm A, in which vinorelbine plus 5000 U of heparin was diluted in 500 ml of normal saline and infused over 2 h, or arm B, in which vinorelbine was diluted in 50 ml of normal saline and infused over 10 min. Arm A with heparin was found to be inferior to arm B in terms of pain control at the injection site. Fasce et al evaluated the influence of infusion time of vinorelbine on local venous toxicity in a randomized cross-over trial [10]. Forty-eight patients with solid tumors were randomized to 6-min infusion or 20-min infusion of vinorelbine. Local venous toxicity was recorded in 23 patients (48%) in the 6-min infusion group, and in 26 patients (56%) in the 20-min infusion group, respectively. On the basis of their results, we used the administration of 6 min infusion of vinorelbine as the control arm in this study. The use of defibrotide [12,13] as another anti-thrombotic drug, or cimetidine [14], which was reported to inhibit histamine actions in endothelial cells by vinorelbine [15], have been investigated in an attempt to reduce the incidence of local venous toxicity of vinorelbine. However, there have been no randomized controlled trials to verify the benefit of these methods, and thus a randomized controlled study is needed to draw definitive conclusions about their efficacy.

In conclusion, our findings indicated that the incidence of local venous toxicity with 1 min bolus of vinorelbine was

higher than previously reported. In our study, the administration of 1 min bolus of vinorelbine did not significantly reduce the incidence of local venous toxicity compared with 6 min infusion. Further studies for the control of local venous toxicity of vinorelbine are warranted.

Acknowledgement

This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan.

References

- [1] Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. *Semin Oncol* 1989;16:2–4.
- [2] Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. *Am J Clin Oncol* 1991;14:115–9.
- [3] Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. *J Clin Oncol* 1993;11:1245–52.
- [4] Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. *Leuk Lymphoma* 1996;22:409–14.
- [5] Brogden JM, Nevidjon B. Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid. *Oncol Nurs Forum* 1995;22:635–46.
- [6] Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, et al. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. *Jpn J Clin Oncol* 2004;34:206–9.
- [7] Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). *Oncol Nurs Forum* 1995;22:707–10.
- [8] Nakayama S, Matsubara N, Sakai T, Aso N. The incidence of phlebitis in the patients administered vinorelbine by intravenous bolus injection—a retrospective study. *Jpn J Cancer Chemother* 2002;29:633–5.
- [9] Lazano M, Muro H, Triguboff E, Schmilovich A, Reate M, Gil DE. A randomized trial for effective prevention of navelbine (NVB) related phlebitis. *Proc Am Soc Clin Oncol* 1995;14:a1766.
- [10] Fasce HM, Machiavelli MR, Tortorella AM, Dominguez ME, Grasso S, Perez JE, et al. Influence of infusion time on the incidence of vinorelbine (VNB)-induced venous irritation (VI) and lower back pain (LBP). *Proc Am Soc Clin Oncol* 2000;19:a2400.
- [11] Thurlimann B, Bachmann I. Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomised trial. *Ann Oncol* 1992;3:311–3.
- [12] Maisano R, Adamo V, Toscano G, Chiofalo G, Pergolizzi S, Scimone A. Defibrotide in the prevention of venous irritation by vinorelbine administration. *Anticancer Res* 1997;17:2775–7.
- [13] Mare M, Maisano R, Caristi N, Adamo V, Altavilla G, Carboni R, et al. Venous damage prevention by defibrotide in vinorelbine-treated patients. *Support Care Cancer* 2003;11:593–6.
- [14] Vassilomanolakis M, Koumakis G, Barbounis V, Orphanos G, Efremidis A. Prevention of vinorelbine phlebitis with cimetidine. A two-step design study. *Support Care Cancer* 2001;9:108–11.
- [15] Estevez MD, Vleytes MR, Louzao MC, Alfonso A, Vilarino N, Botana LM. The antineoplastic drug vinorelbine activates non-immunological histamine release from rat mast cells. *Inflamm Res* 1997;46:119–24.



SHORT COMMUNICATION

Sequential occurrence of non-small cell and small cell lung cancer with the same *EGFR* mutation

Ryotaro Morinaga^a, Isamu Okamoto^{a,*}, Kazuyuki Furuta^b, Yukiko Kawano^b, Masaru Sekijima^b, Kensaku Dote^c, Takao Satou^d, Kazuto Nishio^e, Masahiro Fukuoka^a, Kazuhiko Nakagawa^a

^a Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan

^b Research Division for Advanced Technology, Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd., Ibaraki, Japan

^c Department of Pathology, Kinki University School of Medicine, Osaka, Japan

^d Division of Hospital Pathology, Kinki University School of Medicine, Osaka, Japan

^e Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan

Received 20 April 2007; received in revised form 14 May 2007; accepted 17 May 2007

KEYWORDS

EGFR mutation;
Non-small cell lung cancer;
Small cell lung cancer

Summary We report a case of small cell lung cancer (SCLC) developing after prolonged treatment (more than 2 years) for primary adenocarcinoma of the lung, and we show that both the SCLC and non-small cell lung cancer (NSCLC) tissues obtained from the same site share the same deletion in exon 19 of *EGFR*. This case suggests that the activating *EGFR* mutations may confer the pathogenesis of a subset of SCLC.

© 2007 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

The identification of somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in patients with NSCLC and the association of such mutations with the clinical response to EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib have had a substantial impact on the treatment of this disease [1,2]. To date,

however, only a few *EGFR* mutations have been detected in other solid tumors including SCLC.

2. Case report

A 46-year-old Japanese woman with no smoking history was diagnosed in July 2003 with stage IIIB adenocarcinoma (acinar type) of the lung, with a primary tumor in the left lower lobe and pleural disseminations. A computed tomography (CT) scan showing the tumor (arrow) and hematoxylin–eosin (HE) staining of a tumor biopsy specimen are shown (Fig. 1A). The patient received first-line treatment with cisplatin and vinorelbine and showed a brief partial response. She

* Corresponding author. Tel.: +81 72 366 0221; fax: +81 72 360 5000.

E-mail address: chi-okamoto@dotd.med.kindai.ac.jp (I. Okamoto).




Fig. 1 Chest CT scan: (A) before treatment and HE staining of a tumor biopsy specimen; (B) before second lung biopsy and HE and synaptophysin stainings of a tumor biopsy specimen; (C) after four cycles of cisplatin and irinotecan; (D) before third lung biopsy and HE and synaptophysin stainings of a tumor biopsy specimen.

subsequently underwent combination chemotherapy with gemcitabine and paclitaxel, manifesting a minor response on radiographic examination. In September 2004, the mass in the left lower lobe had progressed and treatment with gefitinib (250 mg daily) was initiated. After 10 months of treatment with gefitinib alone and transient disease stabilization, a repeat evaluation in July 2005 showed progression of the primary lung tumor. Gefitinib was discontinued, and the patient was enrolled in a phase I clinical trial of new agents. The primary tumor showed no evidence of regression on radiological examination. A magnetic resonance imaging (MRI) scan in December 2005 revealed multiple brain metastases in both hemispheres, which were accompanied by symptoms including headache, nausea, and visual disturbances. After surgical resection of the largest tumor in the right parietal lobe, the patient was exposed to 10 fractions of 3 Gy whole-brain radiotherapy. Her symptoms improved markedly, and MRI scans after radiotherapy revealed almost complete regression of the brain metastases. Histological examination of the resected brain tumor revealed a synaptophysin-positive small cell cancer. The patient provided informed consent to repeated lung biopsies for histological examination. A biopsy specimen of the progressive mass in the left lower lobe in February 2006 revealed SCLC by HE staining and was positive for synaptophysin by immunohistochemical analysis (Fig. 1B). A second lung biopsy

specimen was microdissected for extraction of genomic DNA and analysis of *EGFR* mutations. A heterozygous in-frame 15-bp deletion in exon 19 of *EGFR* was detected with the use of the amplification refractory mutation system (ARMS); the genomic DNA of the patient was thus subjected to amplification by the polymerase chain reaction with primers specific for the wild-type (Fig. 2A, left panel) or mutant (Fig. 2A, right panel) versions of exon 19. The deletion was confirmed to be delE746–A750 by nucleotide sequencing. On the basis of the histological diagnosis of SCLC, the patient was treated with four cycles of cisplatin and irinotecan, and she achieved a partial response (Fig. 1C). A repeat chest CT evaluation in August 2006 showed progression of the primary lung tumor (Fig. 1D). A new lung biopsy specimen revealed nests of adenocarcinoma cells forming small tubular structures, the same subtype of the adenocarcinoma at initial diagnosis on July 2003, and was negative for synaptophysin staining (Fig. 1D). In addition, ARMS analysis of the adenocarcinoma specimen detected the same in-frame 15-bp deletion in exon 19 of *EGFR* that had been identified in the previous SCLC specimen (Fig. 2B).

3. Discussion

EGFR mutations are more frequent in women, Asians, individuals with adenocarcinoma, or those who have never




Fig. 2 Results of ARMS analysis of (A) the SCLC. Ascending curves, performed in duplicate (green and red), indicate that wild type (left panel) and deletion mutation in exon 19 (right panel) were detected; (B) the adenocarcinoma. Ascending curves, performed in duplicate (green and red), indicate that wild type (left panel) and deletion mutation in exon 19 (right panel) were detected.


smoked [3–5]. However, EGFR expression has been shown to be low or undetectable in SCLC, and screening of SCLC for EGFR mutations has yielded negative results [5]. We previously described the first case of SCLC with a deletion in exon 19 of EGFR in a nonsmoking Japanese woman [6]. Another case of SCLC with an 18-bp deletion in exon 19 of EGFR in a nonsmoking woman was also recently reported [7]. All reported cases of SCLC with EGFR mutations, including the present case, have thus been in women who have never smoked, even though SCLC occurs almost exclusively in smokers. Furthermore, all three of these SCLC cases were initially diagnosed as adenocarcinoma. In the present case, SCLC developed after prolonged treatment (>2 years) for primary adenocarcinoma, and both SCLC and NSCLC (adenocarcinoma) tissues obtained from the same site shared the same EGFR mutation. Small cell carcinoma of the prostate, which shares histological similarities with SCLC, has been shown to arise during the course of treatment for prostatic adenocarcinoma, suggesting that prostatic small cell carcinoma may originate from multipotent stem cells of the prostate that have the ability to differentiate into either epithelial or neuroendocrine type carcinoma [8–10]. It remains unclear whether the primary tumor of the present patient originally had a minor SCLC component or whether SCLC arose from transdifferentiation of the adenocarcinoma. Our finding that SCLC and NSCLC developed at the same site in the lung and shared the same somatic EGFR mutation suggests, however, that different types of lung cancer may arise from a common stem cell with multiple potential pathways of differentiation.

Conflict of interest

We, all authors, indicate no potential conflicts of interest.

References

- [1] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
- [2] Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA* 2004;101:13306–11.
- [3] Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497–500.
- [4] Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Res* 2004;64:8919–23.
- [5] Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005;97:339–46.
- [6] Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. *Ann Oncol* 2006;17:1028–9.
- [7] Zakowski MF, Ladanyi M, Kris MG. EGFR mutations in small-cell lung cancers in patients who have never smoked. *N Engl J Med* 2006;355:213–5.
- [8] Valle J, von Boguslawsky K, Stenborg M, Andersson LC. Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels. *Scand J Urol Nephrol* 1996;30:509–12.
- [9] Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. *BJU Int* 2001;88:982–3.
- [10] Trotz C. Prostate cancer with a normal PSA: small cell carcinoma of the prostate—a rare entity. *J Am Board Fam Pract* 2003;16:343–4.



Skeletal metastases in non-small cell lung cancer: A retrospective study

Asuka Tsuya^{a,*}, Takayasu Kurata^b, Kenji Tamura^c, Masahiro Fukuoka^a

^a Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama City, Osaka 589-8511, Japan

^b Department of Medical Oncology, Hyogo Medical Center for Adults, 13-70 Kita-Ohji Town, Akashi City, Hyogo 673-8558, Japan

^c Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, 1248-1 Otsuta Town, Ikoma City, Nara 1248-1, Japan

Received 15 November 2006; received in revised form 14 February 2007; accepted 12 March 2007

KEYWORDS

Skeletal metastasis;
Skeletal-related event;
Retrospective study;
Median survival;
Non-small cell lung cancer;
Bisphosphonate

Summary

Background: The skeleton is one of the most common sites of metastasis in patients with advanced cancer. Bone metastases often cause SREs (skeletal-related events). Despite advances in the treatment of primary lung cancer, SREs still affect many patients. Therefore, we planned a retrospective study to investigate the clinical impact of SREs, and to compare differences in the therapeutic outcome between patients with and without skeletal metastases or SRE.

Patients and methods: We retrospectively investigated the charts of all 259 patients with non-small cell lung cancer (NSCLC) who consulted the Department of Medical Oncology at Kinki University School of Medicine between February 2002 and January 2005. We assessed their TNM stage, presence of skeletal metastases (on bone scintigraphy, MRI, and plain X-ray films), and outcome parameters such as SREs, analgesic use, and survival.

Results: A total of 70 patients (30.4%) were found to have skeletal metastases during their clinical course and 35 patients (50%) out of all 70 patients had SREs. Among 135 stage IV patients, a total of 56 (41%) had skeletal metastases, and 25 of these 56 patients (45%) had SREs. The most common SREs were the need for radiotherapy (34.3%) and hypercalcemia (20%). Patients with SREs tended to have worse survival, while no significant difference of survival was observed between patients with and without skeletal metastases.

Conclusion: It seems to be important to prevent SREs during the treatment of NSCLC, so further studies evaluating bisphosphonates in combination with chemotherapy are warranted.

© 2007 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Most patients with advanced cancer develop skeletal metastases during the course of their disease, and these are often associated with significant morbidity [1]. The major-

* Corresponding author. Tel.: +81 72 366 0221;
fax: +81 72 360 5000.
E-mail address: a.tsuya@scchr.jp (A. Tsuya).

ity of bone metastases arise from primary tumors of the breast, prostate, thyroid, or lung among others. In Western countries, it has been reported that the incidence of bone metastases in lung cancer patients is approximately 30–40%, and the median survival time (MST) of patients with such metastases is 7 months [2]. A more recent retrospective review of 435 patients with non-small cell lung cancer (NSCLC) revealed an incidence of 24% for skeletal metastases. In this review, the majority of skeletal metastases (66%) were detected at the time of initial staging [3]. Bone is a common site of cancer spread, ranking only behind the liver and the lungs in frequency.

Despite advances in the treatment of primary lung cancer, skeletal-related events (SREs) still affect many patients during their clinical course. Common complications of skeletal metastasis include bone pain, symptomatic pathologic fracture, spinal cord compression, and hypercalcemia of malignancy (HCM). These complications often require surgery to correct fractures or spinal deformities and/or radiation therapy to control the severe pain that is a hallmark of bone metastases. Pain due to bone metastases is the most frequent form of pain reported by cancer patients [4]. Thus, SREs have a negative impact on the quality of life, performance status, and function of cancer patients.

Although skeletal metastases due to lung cancer have already attracted attention in Western countries, little is known about the incidence of bone metastases arising from lung cancer in Japan. Therefore, we planned a retrospective study to investigate the clinical impact of SREs and to explore the therapeutic outcome of patients with or without skeletal metastases and/or SREs.

2. Patients and methods

2.1. Study population

We retrospectively investigated 259 patients with NSCLC who consulted the Department of Medical Oncology at Kinki University School of Medicine between February 2002 and January 2005.

The TNM stage, the presence of skeletal metastases (on bone scintigraphy, MRI, and plain X-ray films), and outcome parameters such as SREs, analgesic use, and survival were investigated.

In this study, SREs were defined as pathologic fracture, spinal cord compression, hypercalcemia, bone radiation therapy (palliative therapy for pain, or treatment/prevention of pathologic fractures and spinal cord compression), and bone surgery (stabilization or decompression).

2.2. Statistical analysis

The characteristics of stages III and IV patients were compared using the χ^2 -test. Survival curves were calculated and drawn by using the Kaplan–Meier method, and differences between stage IV patients with or without SREs were assessed by the log–rank test. All analyses were two-sided. Statistical software (Statistical Package SAS Software release 8.2) was used for statistical analysis, and $p < 0.05$ was considered statistically significant.




Fig. 1 Incidence of skeletal metastases and SREs in patients presenting with stage IV disease.

3. Results

3.1. Patients

We retrospectively investigated 259 NSCLC patients who visited and consulted the department of Medical Oncology, Kinki University School of Medicine, between February 2002 and January 2005. A total of 29 patients were excluded because of early stage disease, so the total number of patients assessed was 230. Among them, 156 patients (68%) were men. The pathologic diagnosis was adenocarcinoma in 140 patients (61%) and most patients had a good performance states (PS 0/1 in 193 patients, or 84%). The median age was 65 years. There were no obvious difference of these characteristics between patients in stage III and stage IV, although statistical analysis was not done.

3.2. Incidence of skeletal metastases

A total of 70 patients (30.4%) were found to have skeletal metastases during their clinical course. Among them, 46 patients (65.7%) had skeletal metastases at the time of initial diagnosis. Thirty-five (50%) of the 70 patients suffered from SREs. Eleven (31%) of the 35 patients had SREs at the time of initial staging, and 24 (69%) of the 35 patients developed SREs due to recurrence of their disease after treatment.

Of the 135 patients who were initially in stage IV, 56 patients (41%) had skeletal metastases, and 25 (45%) of these 56 patients suffered from SREs. Among the 56 patients with skeletal metastases, 46 patients (82%) had these metastases at the time of initial staging, while 11 (44%) of the 25 patients with SREs already had them at initial staging (Fig. 1).

A total of 95 patients were initially in stage III. After treatment of their cancer, 14 patients developed skeletal metastases and 10 (71%) of them suffered from SREs (Fig. 2).

3.3. Sites of skeletal metastasis

Table 1 shows the sites of skeletal metastasis. The spine was the most common site (50%), followed by the ribs (27.1%).




Fig. 2 Incidence of skeletal metastases and SREs in patients presenting with stage III disease.

Table 1 Sites of skeletal metastasis (n=70)

Spine	35 (50.0%)
Ribs	19 (27.1%)
Ilium	7 (10.0%)
Sacrum	5 (7.1%)
Femur	4 (5.7%)
Skull	4 (5.7%)
Humerus	2 (2.9%)
Scapula	2 (2.9%)
Sternum	2 (2.9%)

3.4. Complications of skeletal metastasis

Table 2 shows the details of SREs. Among 70 patients with skeletal metastases, a total of 35 (50%) developed SREs. The most common SRE was bone radiation therapy in 24 patients (34.3%), followed by hypercalcemia in 14 patients (20%). Spinal cord compression occurred in 11 patients (15.7%).

3.5. Analgesic use

Among the 70 patients with skeletal metastases, 55 (78.6%) had localized bone pain, and 39 (70%) of the 55 patients required NSAIDs for pain relief, while 40 (73%) of them required opioids.

3.6. Survival

The MST was 679 days for stage III patients and 447 days for those with stage IV disease.

Fig. 3 shows survival of the patients who had stage IV disease with or without skeletal metastases. For patients with

Table 2 Individual SREs in 35 out of 70 patients with skeletal metastases

1	Radiation to bone	24 cases: 34.3%
2	Hypercalcemia	14 cases: 20.0%
3	Spinal cord compression	11 cases: 15.7%
4	Pathologic fracture	5 cases: 7.1%
5	Surgical stabilization/decompression	0 cases: 0%
	Localized bone pain	55 cases: 78.6%




Fig. 3 Overall survival of stage IV patients with and without skeletal metastases.

Table 3 MST of patients presenting in stages III or IV

	N	MST (days)
Stage IV		
BM (-)	79	268
BM (+)	56	237
BM (+)		
SRE (+)	25	187
SRE (-)	31	366
Stage III		
BM (-)	81	314
BM (+) ^a	14	298
BM (+)		
SRE (+)	10	240
SRE (-)	4	255

^a Following initial treatment.

skeletal metastases, MST was 237 days, while it increased to 268 days for those without such metastases. However, there was no statistically significant difference of survival between patients with and without skeletal metastases ($p=0.733$). Interestingly, the MST was 187 days for stage IV patients with SREs, while it was 366 days for patients without SREs (Table 3), but this difference also failed to reach statistical significance. The median time to the first SRE was 182 days for patients presenting with stage III disease and 93 days for those presenting with stage IV disease, while the MST from the date of the first SRE was 40 days for stage III patients and 138 days for stage IV patients. The MST from the date of the first SRE was 92 days for all patients with SRE.

4. Discussion

As far as we know, this is the first report about the frequency and influence on survival of skeletal metastases and SREs in Japanese lung cancer patients. Our results were similar to 1997 data from the USA [2]. A total of 70 patients (30.4%) were noted to have skeletal metastases during their clinical course, as did 56 patients (41%) with stage IV disease at the time of diagnosis.

Our study also showed that the most common SRE was radiation therapy for bone metastases (34.3%), followed by hypercalcemia (20%), and spinal cord compression (15.7%).

On the other hand, the major SREs in western countries were radiation therapy for bone metastases in 49.9%, hypercalcemia in 8.0%, cord compression in 5.8%, and bone surgery in 12.6%. Compared with Japanese data, the frequency of surgery seems to be higher.

In our analysis, the MST of patients with skeletal metastases was 7.9 months and there was no significant difference of survival between the patients with and without skeletal metastases ($p=0.733$). A total of 50% of the patients with skeletal metastases had SREs according to this retrospective study, which is similar to the results from Western countries [5–7].

Interestingly, the MST of our lung cancer patients with SREs was only half of that for patients without SREs (6.2 months for patients with SREs versus 12.2 months for patients without SREs). The lack of a significant difference may have been attributable to our small sample size. There seem to be two main reasons why the prognosis of lung cancer patients with SREs is poor. One is that they are unable to receive appropriate or sufficiently aggressive treatment because of deterioration of PS due to SREs. The other is that tumors associated with SREs may be chemoresistant because these lesions have progressed more, even if it is possible to treat them. Therefore, it is more important to prevent SREs than to treat them. In this study, the median time to the first SREs was 3.1 months in patients with stage IV disease. If this period could be extended, more patients would be able to receive second-line and third-line treatment for lung cancer. It is a well-known fact that bisphosphonates is effective in the treatment for hypercalcemia which is one of SREs [8,9]. Recently, bisphosphonates have been shown to be effective for the prevention of SREs in patients with various tumors, particularly breast cancer, prostate cancer, and multiple myeloma [10–13]. Saad et al. conducted a placebo-controlled trial of a new bisphosphonate (zoledronic acid) in patients with hormone-refractory metastatic prostate carcinoma and reported that it significantly reduced SREs and also significantly increased the time to the first SRE [14]. With regard to NSCLC, there has only been one study that evaluated the influence of bisphosphonates on SREs and the time to the first SRE [6]. However, as half of the subjects did not have NSCLC in that study and it was the only trial done previously, no consensus about the value of bisphosphonates for skeletal metastases of NSCLC has been obtained.

The present retrospective study revealed that the prognosis of NSCLC patients with SREs was worse than that of patients without SREs, while there was no survival difference between patients with and without skeletal metastases. Although it is unclear whether it is important to delay the time to the first SRE in NSCLC patients because of their poor prognosis, our data may support the clinical development of bisphosphonates. These drugs have also demonstrated antitumor activity in preclinical models through inhibition of angiogenesis and by the inhibition of cell proliferation and cell adhesion [15]. Therefore, the West Japan Thoracic Oncology Group is planning a randomized clinical trial to compare the combination of chemotherapy and zoledronic acid with chemotherapy alone for NSCLC patients with skeletal metastases. The aim is to examine

whether this combination has a survival benefit through delaying SREs and through the antitumor activity of zoledronic acid.

References

- [1] Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastases. *Cancer* 1997;80:1529–37.
- [2] Coleman RE. Skeletal complications of malignancy. *Cancer* 1997;80:1588–94.
- [3] Kosteva J, Langer CJ. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. *Lung Cancer* 2004;46(Suppl 1):S45 [Abstract].
- [4] Mercadante S. Malignant bone pain: pathophysiology and treatment. *Pain* 1997;69:1–18.
- [5] Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. *Oncology* 2004;67:390–6.
- [6] Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. *J Clin Oncol* 2003;21:3150–7.
- [7] Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors; a randomized phase III, double-blind, placebo-controlled trial. *Cancer* 2004;100:2613–21.
- [8] Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. *J Bone Miner Res* 1999;14:1557–61.
- [9] Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy; a pooled analysis of two randomized, controlled clinical trials. *J Clin Oncol* 2001;19:558–67.
- [10] Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Mortley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. *Cancer* 2001;91:1191–200.
- [11] Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma; a randomized, double blind, multicenter, comparative trial. *Cancer* 2003;98:1735–44.
- [12] Saad F, Gleason DM, Murray R. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. *J Urol* 2003;169(Suppl) [Abstract 394].
- [13] Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. *J Natl Cancer Inst* 2004;96(11):879–82.
- [14] Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 2002;94:1458–68.
- [15] Green JR. Bisphosphonates: preclinical review. *Oncologist* 2004;9:3–13.

Sublobar Resection for Patients With Peripheral Small Adenocarcinomas of the Lung: Surgical Outcome is Associated With Features on Computed Tomographic Imaging

Haruhiko Nakayama, MD, Kouzo Yamada, MD, Haruhiro Saito, MD, Fumihiko Oshita, MD, Hiroyuki Ito, MD, Yoichi Kameda, MD, and Kazumasa Noda, MD

Divisions of Thoracic Surgery, Thoracic Oncology, and Pathology, Kanagawa Cancer Center, Yokohama, Japan

Background. Sublobar resection for peripheral small adenocarcinomas of the lung remains controversial. We studied the feasibility of deciding whether to perform limited pulmonary resection on the basis of preoperative images obtained by high-resolution computed tomography.

Methods. A total of 123 patients with adenocarcinoma of the lung underwent sublobar resection of clinical T1N0M0 tumors measuring 2 cm or less in diameter on high-resolution computed tomography. Patients with multiple lung cancers or a history of lung cancer or other malignancies were excluded. The remaining 63 patients were studied. All tumors were classified as "air-containing type" or "solid-density type" according to the tumor shadow disappearance rate on high-resolution computed tomography. We evaluated the surgical outcomes of sublobar resection with respect to findings on high-resolution computed tomography images.

Results. Forty-six patients had air-containing type tumors (tumor shadow disappearance rate $\geq 50\%$), and 17

had solid-density type tumors (tumor shadow disappearance rate $< 50\%$). Forty-nine wedge resections and 14 segmentectomies were performed. Wedge resection was the most common procedure in patients with air-containing type tumors. Pathologically, air-containing type tumors comprised 38 bronchioloalveolar carcinomas and 8 nonbronchioloalveolar carcinomas. No patient with air-containing type tumors had recurrence after a median follow-up of 70 months (range, 21 to 133 months). Overall and relapse-free survival rates at 5 years were 95% and 100%, respectively, in patients with air-containing type tumors, as compared with 69% and 57%, respectively, in those with solid-density type tumors.

Conclusions. Sublobar resection might be an acceptable procedure for the treatment of small air-containing type adenocarcinomas of the lung on preoperative high-resolution computed tomography. However, our findings must be confirmed in larger, multicenter studies.

(Ann Thorac Surg 2007;84:1675-9)

© 2007 by The Society of Thoracic Surgeons

Lobectomy has been established as the procedure of choice for most peripheral, clinical T1 N0 M0 lung cancers. This recommendation was based on the results of a randomized trial performed by the Lung Cancer Study Group, showing that sublobar resections, ie, segmental or wedge resections, had a significantly higher risk of locoregional recurrence [1]. However, increased use of computed tomography (CT) and improved scanning techniques after the 1980s, when the Lung Cancer Study Group trial was performed, have enhanced the detection rate of small cancers, leading thoracic surgeons to reassess the potential benefits of sublobar resection for small peripheral lung cancers [2-4]. Important advances have also been made in pathologic and CT evaluations of adenocarcinoma of the lung, especially bronchioloalveolar carcinoma (BAC) [5, 6].

Accepted for publication March 5, 2007.

Address correspondence to Dr Nakayama, Division of Thoracic Surgery, Kanagawa Cancer Center, 1-1-2, Nakao, Asahi-ku, Yokohama, 241-0815, Japan; e-mail: nakayama-h@kccch.jp.

© 2007 by The Society of Thoracic Surgeons
Published by Elsevier Inc

We previously reported that the tumor shadow disappearance rate (TDR) on high-resolution CT (HRCT), defined as the ratio of the tumor area of the mediastinal window to that of the lung window, closely reflected the biologic characteristics of small peripheral adenocarcinomas of the lung. Tumors with a TDR of 50% or higher showed no lymph node involvement and rarely had microscopic invasion. Such tumors might therefore be appropriate candidates for limited pulmonary resection [7, 8]. In this study, we analyzed follow-up data in patients in whom sublobar resection was performed on the basis of HRCT findings. We focused on the outcomes of limited pulmonary resection in patients with early adenocarcinomas of the lung on radiologic evaluation.

Patients and Methods

Our ethics committee was informed of this retrospective study and gave their approval for publication. Individual patient consent was waived by the chairman



Fig 1. High-resolution computed tomographic image of air-containing type adenocarcinoma (tumor shadow disappearance rate $\geq 50\%$).

of the ethics committee. Between July 1992 and October 2004, 329 patients with adenocarcinoma of the lung underwent complete resection of clinical T1 N0 M0 tumors measuring 2 cm or less in diameter on HRCT at our hospital. Preoperative evaluation included a detailed history and physical examination, chest radiography, CT of the chest and upper abdomen, and bone scintigraphy for staging and assessment of resectability.

Chest images were acquired with a model TCT 900S Super HELIX or X-Vigor/Real CT scanner (Toshiba Medical Systems, Tokyo, Japan). High-resolution images targeted to the tumor were obtained continuously at 120 kVp and 200 mAs, with 2-mm section thickness, pitch 1, 1- to 2-mm section spacing, 512 \times 512 pixel resolution, 1-second scanning time, and a high spatial reconstruction algorithm with a 20-cm field of view. Images were photographed onto each sheet of film using the mediastinal (level, 40 HU; width, 400 HU) and lung (level, -600 HU; width, 1,600 HU) window settings. As previously reported [7, 8], we classified tumors into two types according to the TDR. Tumor shadow disappearance rate was defined as follows:

$$\text{TDR} = 1 - \frac{\text{tumor area of the mediastinal windows}}{\text{tumor area of the lung windows}}$$



Fig 2. High-resolution computed tomographic image of solid-density type adenocarcinoma (tumor shadow disappearance rate $< 50\%$).

Table 1. Clinical and Pathologic Characteristics of Patients


Characteristic	Type of Lesion on HRCT		p Value
	Air-Containing Type (n = 46)	Solid-Density Type (n = 17)	
Age			0.7985
Range (years)	43-84	46-79	
Mean (years)	63	64	
Sex			0.5896
Male	19	9	
Female	27	8	
Operative mode			0.2397
Wedge resection	38	11	
Segmentectomy	8	6	
Size (mm) ^a			<0.0001
Range	3-20	7-20	
Mean	10.5	15.6	
Pathologic stage			0.0243
T1	46	14	
T2 ^b	0	3	
Histologic subtype			<0.0001
BAC	38	0	
Non-BAC	8	17	
Pleural involvement			0.0001
p0/p1/p2	46/0/0	11/3/3	
Blood vessel invasion			<0.0001
Present/absent	0/46	7/10	
Lymphatic invasion			0.0048
Present/absent	0/46	4/13	

^a Size of resected specimen was measured grossly. ^b Visceral pleural invasion discovered.

BAC = bronchioloalveolar carcinoma; HRCT = high-resolution computed tomography.

A TDR of 50% or greater was defined as "air-containing type" (Fig 1), and a TDR of less than 50% was defined as "solid-density type" (Fig 2).

Among the 329 patients who underwent complete resection of small adenocarcinomas, lobectomy was performed in 206 (92 with air-containing type, 114 with solid-density type), and sublobar resection was performed in 123 (78 with air-containing type, 45 with solid-density type). Fifty-one patients who underwent sublobar resection were considered unsuitable candidates for lobectomy because of limited pulmonary function or other comorbidities. These patients were considered to have undergone compromised resections. Based on the results of lobectomy with lymph node dissection for the air-containing type tumors, which showed no lymph node involvement and rarely had microscopic invasion [7, 8], we started to perform intentional sublobar resection in patients with air-containing type tumors in 1995 after obtaining complete, written informed consent from each patient. Intentional sublobar resection was defined as wedge resection or segmentectomy for patients who were considered suitable candidates for lobectomy. Intentional sublobar resections were performed for



Patients at risk						
Months	0	12	24	36	48	60
Air-containing type	46	46	45	42	36	30
Solid-density type	17	17	14	12	8	7

Fig 3. Overall survival curve for patients with air-containing type (solid line; n = 46) and solid-density type (dotted line; n = 17) tumors.


air-containing type tumor on CT images, provided they were located in the outer third of the lung parenchyma. Wedge or segmental resection was performed on the basis of only lesion location and size, and the procedure was selected to achieve adequate resection margins. Sixty-eight patients underwent intentional sublobar resection. The other 4 patients with solid-density type tumors on HRCT underwent sublobar resection because metastatic lung cancer or low-grade malignant tumors were diagnosed on frozen section analysis during operation. Among 123 patients who underwent sublobar resection, a total of 60 patients were excluded because they had a history of previously treated cancer or malignancy of other organs (21 patients), multiple lung cancers (27 patients), or second lung cancers detected during follow-up after resection of their primary lung cancers (12 patients). The remaining 63 patients were studied retrospectively.

Tumor types on HRCT were compared with respect to pathologic findings and surgical outcomes. Pathologic findings included pathologic TNM stage, histologic type of adenocarcinoma, pleural involvement, vessel invasion, and lymphatic invasion. The histologic type of adenocarcinoma and TNM stage were determined according to the World Health Organization classification [9] and UICC staging system [10]. Pleural involvement was defined according to the Japanese Lung Cancer Society classification [11]: p0, visceral pleura is not involved by tumor; p1, tumor has reached but not invaded the visceral pleura; and p2, tumor has invaded the visceral pleura but does not involve the parietal pleura. Briefly, p0 and p1 are classified as T1 disease, and p2 as T2 disease. Survival was calculated by the Kaplan-Meier method, and differences in survival were determined by the

log-rank test. Unpaired two-tailed Student's *t* tests were used to compare mean values. The χ^2 test was used to compare observed percentages. Differences with probability values of less than 0.05 were considered statistically significant.

Results

The 63 patients ranged in age from 43 to 84 years (median, 67 years) and comprised 28 men and 35 women. The clinical and pathologic findings of the patients according to tumor type on HRCT are summarized in Table 1. Eleven air-containing type tumors showed pure ground-glass opacity (GGO), defined as a hazy increase in lung attenuation without obscuring the underlying vascular markings on HRCT. Among the patients with air-containing type tumors, intentional sublobar resection was performed in 39 (85%) and compromised resection in 7. On the other hand, 15 (88%) of the 17 patients with solid-density type tumors underwent compromised sublobar resection; in the other 2 patients low-grade malignant tumors were diagnosed on frozen section analysis during operation. As for the type of surgical resection, 49 wedge resections (78%) and 14 segmentectomies (22%) were performed. Most (83%) of the patients with air-containing type tumors underwent wedge resections. Because most of the sublobar resections in the patients with solid-density type tumors were compromised procedures, wedge resection was more common than segmental resection in these patients. Lymph-node sampling was done in 8 patients with air-containing type tumors. As for the patients with solid-density type tumors, lymph-node sampling was done in 6 patients and dissection in 2. The other 9 patients (53%) with solid-



Patients at risk						
Months	0	12	24	36	48	60
Air-containing type	46	46	45	42	36	30
Solid-density type	17	15	13	11	7	5

Fig 4. Relapse-free survival curve for patients with air-containing type (solid line; n = 46) and solid-density type (dotted line; n = 17) tumors.

density type tumors had limited cardiopulmonary reserve; lymph node exploration was considered not to be beneficial mainly because of calcified nodes, dense pleural adhesion, and hypoxemia during operation.

Histopathologically, none of the patients with air-containing type tumors had vascular invasion or pleural involvement; however, 8 (17%) were given a diagnosis of not pure BAC (adenocarcinoma with mixed subtypes) because of minimal stromal invasion. In contrast, all solid-density type tumors were non-BACs associated with high rates (47% of all solid-density type tumors) of pleural involvement or vascular invasion.

There were no serious complications after operation and no surgical mortality. Two patients with air-containing type tumors and 1 with a solid-density type tumor died of other diseases, with no evidence of recurrence. Seven patients with solid-density type tumors died of recurrent lung cancer; the first site of recurrence was locoregional in 5 patients (3 wedge resections, 2 segmentectomies) and liver metastasis in 2 (1 wedge resection, 1 segmentectomy). The sites of locoregional recurrence were pleural dissemination in 2 patients (1 wedge resection, 1 segmentectomy), pulmonary metastasis in 2 (1 wedge resection, 1 segmentectomy), and mediastinal lymph node in 1 (wedge resection). No patient with air-containing type tumors had recurrence. Overall and relapse-free survival curves are shown in Figures 3 and 4. Median follow-up of the survivors was 70 months (range, 21 to 133 months) in patients with air-containing type tumors and 49 months (range, 25 to 112 months) in those with solid-density type tumors. Overall and relapse-free survival rates at 5 years were 95% and 100%, respectively, in patients with air-containing type tumors, as compared with 69% and 57%, respectively, in those with solid-density type tumors. Both survival rates were significantly better in patients with air-containing type tumors than in those with solid-density type tumors ($p < 0.0001$).

Comment

Lobectomy remains the standard operation for small non-small-cell lung cancers. The role of intentional sublobar resection for these tumors should be evaluated in well-designed clinical trials. At present, there are two possible indications for intentional sublobar resection. The first is for clinically diagnosed very early lung cancers, usually defined as clinical T1 N0 M0 tumors 2 cm or less in diameter that are located in the periphery of the lung. Because lymph node metastasis accompanies approximately 15% of adenocarcinomas of this size [12], N0 status must be confirmed at operation. In most series of patients undergoing sublobar resection for clinically very early lung cancers, segmental resection is the procedure of choice to gain access to the hilar lymph nodes [2-4]. In addition, segmentectomy for confirming N0 status should be selected in the patients with adenocarcinomas of solid-density type on HRCT because nodal involvement was found in 12% of these patients [7].

The other possible indication for intentional sublobar resection is pathologically confirmed noninvasive adenocarcinoma of the lung. The histologic classification of the World Health Organization defines BAC as noninvasive adenocarcinoma showing pure lepidic growth without vascular, stromal, or pleural invasion [9]. Lymph node metastasis has not been found in patients with BAC, and cure is likely after complete resection [5]. An improved understanding of the pathologic characteristics of peripheral lung adenocarcinoma and increased use of CT scanning has led interest to focus on the correlation of CT images with the histologic features of BAC. Attempts have been made to identify CT findings that could serve as landmarks for sublobar resection [6-8, 13-18]. Bronchioalveolar carcinoma components showing lepidic growth along alveoli, without areas of invasion, present as areas of GGO on HRCT [14]. The proportion of GGO is directly related to tumor histology and behavior. Patients with adenocarcinomas measuring 2 cm or less in which the proportion of GGO to the whole tumor area on HRCT was 50% or greater have no lymph node involvement and survive without any recurrence after resection [13, 15]. The TDR on HRCT images is also a simple and useful index for identifying early adenocarcinoma of the lung [7, 8, 16]. Visual evaluation of the GGO ratio is subject to considerable variability among examiners [18]. In contrast, evaluation of the TDR on HRCT has the advantage of simplicity and does not require the use of complex instrumentation: tumor opacity on lung window images is simply compared with that on mediastinal images [7]. Okada and colleagues [16] reported that the extent of both TDR and GGO correlate well with that of the BAC growth of adenocarcinomas; however, the TDR more strongly correlates with the BAC proportion than does the GGO ratio. Previously, we also reported that adenocarcinomas measuring 2 cm or less in diameter in which the TDR on HRCT was 50% or greater have no lymph node involvement and rarely show microscopic invasion. These findings suggested that sublobar resection might be an appropriate approach for the management of such tumors [7, 8]. Few studies have evaluated the outcomes of sublobar resections performed on the basis of HRCT characteristics other than pure GGO. We therefore retrospectively investigated surgical outcomes in patients who underwent sublobar resections according to findings on preoperative HRCT images.

The outcomes of sublobar resection for these possibly indolent tumors should be assessed on the basis of long-term disease-free survival and recurrence patterns. We therefore excluded patients who had a history of previous primary lung cancers or other malignancies, as well as those with multiple lung cancers. About half of the initially screened patients with these small-sized adenocarcinomas of the lung who underwent sublobar resection were excluded. In our series, all patients with air-containing type tumors, excluding 2 who died of other diseases, survived with no evidence of recurrence, despite incomplete lymph node exploration. Sublobar resections for these air-containing type tumors did not require lymph node sampling or dissection, and the

extent of resection depended on only lesion size or location. In addition, not all of the air-containing type lesions were diagnosed as BAC, whereas 8 (17%) were diagnosed as mixed adenocarcinomas with minimal stromal invasion. Those patients who had BAC with focal or minimal invasion survived with no relapse for 41 to 82 months (median, 51 months) after operation. This result suggested that some patients with radiologic evidence of early lung adenocarcinoma on the basis of TDR show minimal invasion on pathologic examination and might be cured by sublobar resection. However, this point remains controversial, and further studies are needed.

In conclusion, our results suggest that the TDR on HRCT images is a simple and useful variable for identifying small adenocarcinomas indicated for limited pulmonary resection. The outcome of sublobar resection for air-containing type lesions may be favorable in patients with curable disease. Larger, multicenter trials are needed to identify HRCT images that more precisely reflect the biologic behavior of these tumors and to assess the surgical outcomes of sublobar resection indicated on the basis of these HRCT images.

This work was supported in part by a grant-in-aid for cancer research (grant 15-1) from the Ministry of Health, Labor and Welfare, Japan.

References

1. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. *Ann Thorac Surg* 1995;60:615-23.
2. Kodama K, Doi O, Higashiyama M, Yokouchi H. Intentional limited resection for selected patients with T1N0M0 non-small-cell lung cancer: a single-institution study. *J Thorac Cardiovasc Surg* 1997;114:347-53.
3. Yoshikawa K, Tsubota N, Kodama K, Ayabe H, Taki T, Mori T. Prospective study of extended segmentectomy for small lung tumors: the final report. *Ann Thorac Surg* 2002;73:1055-9.
4. Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. *J Thorac Cardiovasc Surg* 2006;132:769-75.
5. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. *Cancer* 1995;75:2844-52.
6. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. *J Clin Oncol* 2005;23:3279-87.
7. Kondo T, Yamada K, Noda K, Nakayama H, Kameda Y. Radiologic-prognostic correlation in patents with small pulmonary adenocarcinomas. *Lung Cancer* 2002;36:49-57.
8. Shimizu K, Yamada K, Saito H, et al. Surgically curable peripheral lung carcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. *Chest* 2005;127:871-8.
9. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histologic typing of lung and pleural tumours. World Health Organization international histological classification of tumours. Berlin: Springer, 1999.
10. Sobin LH, Wittekind Ch, eds. International Union Against Cancer (UICC): TNM classification of malignant tumors, 6th ed. New York: Wiley-Liss, 2002.
11. The Japan Lung Cancer Society. Classification of lung cancer, 1st English ed. Tokyo: Kanahara, 2000.
12. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell carcinomas: are these carcinomas candidates for video-assisted lobectomy? *J Thorac Cardiovasc Surg* 1996;111:1125-34.
13. Kodama K, Higashiyama M, Yokouchi H, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. *Lung Cancer* 2001;33:17-25.
14. Kuriyama K, Seto M, Kasugai T, et al. Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma. *AJR Am J Roentgenol* 1999;173:465-9.
15. Matsuguma H, Yokoi K, Anraku M, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis. *J Thorac Cardiovasc Surg* 2002;124:278-84.
16. Okada M, Nishio W, Sakamoto T, et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinoma. *J Thorac Cardiovasc Surg* 2004;127:857-61.
17. Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H. Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognosis. *Ann Thorac Surg* 2006;81:413-20.
18. Nakata M, Sawada S, Yamashita M, et al. Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2005;129:1226-31.

Susceptibility to Lung Cancer and Genetic Polymorphisms in the Alcohol Metabolite-related Enzymes Alcohol Dehydrogenase 3, Aldehyde Dehydrogenase 2, and Cytochrome P450 2E1 in the Japanese Population

Yuji Minegishi, MD^{1,2,3}
 Hiromasa Tsukino, MD⁴
 Manabu Muto, MD⁵
 Koichi Goto, MD¹
 Akihiko Gemma, MD³
 Shoichiro Tsugane, MD⁴
 Shoji Kudoh, MD³
 Yutaka Nishiwaki, MD¹
 Hiroyasu Esumi, MD²

¹ Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

² Cancer Physiology Project, National Cancer Center Research Institute East, Chiba, Japan.

³ Division of Pulmonary Medicine, Infection Disease, and Oncology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

⁴ Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan.

⁵ Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.

Supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan.

Address for reprints: Yuji Minegishi, MD, Division of Pulmonary Medicine, Infection Disease and Oncology, Department of Internal Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602 Japan; Fax: (011) 81-3-5685-3075; E-mail: yminegls@nms.ac.jp

Received July 2, 2006; revision received March 14, 2007; accepted March 15, 2007.

© 2007 American Cancer Society
 DOI 10.1002/cncr.22795
 Published online 8 June 2007 in Wiley InterScience (www.interscience.wiley.com).

BACKGROUND. It is believed that acetaldehyde plays an important role in alcohol-related carcinogenesis; although current epidemiologic studies have provided inconsistent findings on the association between alcohol consumption and the risk of lung cancer.

METHODS. To clarify the hypothesis that genetic polymorphisms in alcohol-metabolizing enzymes may influence susceptibility to lung cancer, the authors conducted a hospital-based case-control study and examined genetic polymorphisms in the alcohol dehydrogenase 3, aldehyde dehydrogenase 2 (*ALDH2*), and cytochrome P450 2E1 genes in 505 patients with histologically confirmed lung cancer and in a group of 256 noncancer controls who provided complete cigarette and alcohol consumption histories. Genotyping was conducted by polymerase chain reaction-restriction fragment-length polymorphism assay.

RESULTS. A significant association was noted between alcohol consumption and lung cancer risk. Thus, using the median value for the controls as the cut-off point, the odds ratios (OR) for light and heavy drinkers were 1.76 and 1.95, respectively (*P* for trend = .012), compared with nondrinkers. In addition, there was a significant trend toward increased risk of lung cancer in drinkers with *ALDH2* variant alleles (*P* for trend <.0001). The adjusted OR for heavy drinkers was 6.15 compared with nondrinkers. Regarding associations between histologic type and genotypes, the *ALDH2* variant allele was significantly less common in patients who had adenocarcinoma compared with controls.

CONCLUSIONS. The current observations suggested a positive association between alcohol consumption and the risk of lung cancer. Drinking may increase the risk, especially among individuals who have the variant *ALDH2* alleles. *Cancer* 2007;110:353-62. 2007 American Cancer Society.

KEYWORDS: lung cancer, alcohol consumption, case-control study, genetic polymorphism, alcohol dehydrogenase 3, aldehyde dehydrogenase 2, cytochrome P450 2E1.

Epidemiologic studies have provided inconsistent results regarding the associations between alcohol consumption and the risk of lung cancer. In general, therefore, the involvement of alcohol in lung cancer etiology has been regarded with skepticism, with any indication of an association being attributed in most instances to confounding factors, such as cigarette smoking.¹ It indeed is difficult to separate the effects of alcohol and smoking because, the 2 tend to be

correlated, but this problem does not automatically exclude the possibility that there is a separate alcohol effect. A panel of experts commissioned by the World Cancer Research Fund and the American Institute for Cancer Research in 1997, after reviewing the epidemiologic evidence, concluded that alcohol intake possibly may increase lung cancer risk.² Although the mechanism by which alcohol may cause cancer remains obscure, many epidemiologic studies have identified chronic alcohol consumption as a significant risk factor for cancers of the oral cavity, pharynx, larynx, and esophagus in humans.³ When investigating the role of alcohol-related carcinogenesis, most studies have concentrated on the type of alcoholic beverage consumed and the amount of daily intake, but this does not fully explain the variance in individual susceptibility to alcohol-related cancer.

Recent reports strongly implicate acetaldehyde, the first metabolite of ethanol, rather than alcohol itself, as responsible for the risk of developing alcohol-related cancers. It has been reported that acetaldehyde causes mutations by DNA adduct formation and inhibition of DNA repair. Moreover, drinking or inhaling acetaldehyde has mutagenic and carcinogenic effects and induced nasal and laryngeal carcinomas in experimental animals.⁴⁻⁸

Ethanol is primarily (80%) oxidized to acetaldehyde by alcohol dehydrogenase (*ADH*), and most of this acetaldehyde is then eliminated by aldehyde dehydrogenase (*ALDH*). However, ethanol and acetaldehyde also are metabolized through the microsomal ethanol-oxidizing system and the microsomal acetaldehyde-oxidizing system, and cytochrome P450 2E1 (*CYP2E1*) is a major contributor to those systems.^{9,10} *CYP2E1* has high oxidation activity and is induced by long-term alcohol intake. These enzymes exhibit wide interindividual variability in their activity, suggesting that the variation may be caused by genetic polymorphisms.

There are several *ADH* subtypes, some of which have genetic variants with altered kinetic properties. *ADH*₃ is polymorphic, and the enzyme encoded by the *ADH*₃¹ allele metabolizes ethanol to acetaldehyde 2.5 times faster than that encoded by the *ADH*₃² allele.¹¹ *ALDH*₂ is a key enzyme in the elimination of acetaldehyde. In individuals with *ALDH*₂², a variant allele that is prevalent among East Asians (eg, 50% prevalence in Japan¹²), the activity of this enzyme is extremely low. The *CYP2E1* variant allele, which is detectable by *Rsa*I digestion (termed the c2 variant), corresponds to higher activity ethanol metabolism and is associated with greater alcohol consumption.¹³⁻¹⁵ Individuals who have 1 or more *ADH*₃¹, *ALDH*₂², and *CYP2E1* c2 alleles accumulate more acetaldehyde in the blood after

drinking ethanol and may be at increased risk for various alcohol-related diseases at similar levels of alcohol intake as individuals who do not carry these alleles. Because the *ADH*₃ variant allele is common in whites, and the *ALDH*₂ and *CYP2E1* variant alleles are found at high frequency in Asians, research on these genes is most advanced regarding alcohol-related diseases and alcohol metabolism.

The association between genetic polymorphisms in these enzymes and susceptibility to some types of cancer has been reported in case-control studies. The *ADH*₃¹ and *ALDH*₂² alleles are associated closely with alcohol-related cancers in the upper aerodigestive tract,¹⁶⁻²¹ and systemic acetaldehydemia has been considered responsible for carcinogenesis in this locality. However, to our knowledge, there are no reports on associations between polymorphisms of *ALDH* and lung cancer risk. In relation to *ADH*, a negative association between genetic variation in *ADH*₃ and lung cancer has been reported recently.²² *CYP2E1* is responsible primarily for the bioactivation of many low-molecular-weight, tobacco-specific carcinogens, including certain nitrosamines, such as *N*-nitrosodimethylamine and *N*-nitrosornicotine. It is possible that the *CYP2E1* c2 variant not only may increase the blood concentration of acetaldehyde but also may activate these carcinogens more strongly. Activated nitrosamines have been linked to the development of numerous cancers. However, results from studies that evaluated the role of *CYP2E1* polymorphisms in relation to lung cancer have been discrepant.²³⁻²⁸ Because previous investigations did not adjust for alcohol consumption and/or did not have sufficient power to distinguish the risk from alcohol consumption, these inconsistent findings may have been caused by variations in *CYP2E1* enzyme activity induced by ethanol.

We conducted a hospital-based case-control study to evaluate whether *ADH*₃, *ALDH*₂, or *CYP2E1* polymorphisms are associated with lung carcinogenesis. The primary endpoint of the current study was to clarify the association between each genetic polymorphism and the risk of lung cancer, controlling for the amount of alcohol consumed and smoking habits. Furthermore, associations between alcohol consumption and lung cancer risk in individuals with variant alleles, again controlling for smoking, and associations between these polymorphisms and histologic characteristics were evaluated.

MATERIALS AND METHODS

Participants

This study was approved by the Institutional Review Board and the Ethics Committee of the National

Cancer Center, Japan. The majority of eligible participants in this study were residents of Chiba and East Tokyo, and all were of Japanese nationality. Personal and clinical data from patients who participated in the Lung Cancer Database Project at the National Cancer Center Hospital East (NCCH-E) and the National Cancer Center Research Institute East were used in the current study. The database includes information on demographic factors, physical symptoms, psychological factors, and lifestyle factors (diet, smoking, etc) obtained from self-reported questionnaires and medical information from the patients' medical charts and blood, DNA, and urine specimens. All patients who were enrolled in the current study had primary lung cancer that was newly diagnosed with histologic or cytologic confirmation at the Thoracic Oncology Division of the NCCH-E, Japan, from September 1997 to June 2000. All patients provided their written informed consent prior to enrolment in this project. Unmatched controls were newly recruited individuals from the population with no history of cancer or other tumors who visited the Thoracic Oncology Division of NCCH-E from March 2002 to May 2003 and were confirmed as cancer-free by appropriate examinations (chest computed tomography scans, bronchofibroscopy, video-assisted thoracoscopic biopsy, etc). The major reasons for visiting the hospital were suspicions of lung cancer on chest x-ray or sputum cytology at their annual medical check-up or referral from other hospitals. Epidemiologic data were collected by personal interview. All individuals in the control group completed the same standardized questionnaire that was completed by the Lung Cancer Database Project participants, including detailed demographic information, history of cancer, occupational and residential history, and detailed information regarding alcohol and tobacco consumption. All participants provided their written consent.

Sample Collection and DNA Extraction

Four milliliters of peripheral venous blood were collected into heparinized tubes. Genomic DNA was purified from peripheral blood lymphocytes using a DNA isolation kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and was stored at 80°C.

Polymorphism Analysis

ADH₃ and *ALDH₂* genotyping was performed by using the polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) method. To prevent the amplification of closely related *ADH₁* and

ADH₂ genes, samples initially were digested with the *Nla*III restriction enzyme (TOYOBO, Osaka, Japan). A 145-base pair (bp) section of the *ADH₃* gene was amplified by PCR using 200 ng of predigested genomic DNA with primers (sense, 5'-GCTTTAAGAGTAAATATTCTGTCCCC-3'; antisense, 5'-AATCTACCTCTzTTCCGAAGC-3'). The PCR product obtained in this manner then was digested directly with restriction enzyme *Ssp*I (TOYOBO). After polyacrylamide gel electrophoresis, *ADH₃* alleles were visualized by ethidium bromide and were photographed under ultraviolet light. The *ADH₃¹* allele produced fragments of 67 bp, 63 bp, and 15 bp; and the *ADH₃²* allele produced fragments of 131 bp and 15 bp.

A 134-bp fragment of the *ALDH₂* gene was amplified by PCR according to a slightly modified method of Harada et al.¹² One hundred fifty nanograms of genomic DNA were mixed with 5 pmol of each primer (sense, 5'-CAAATTACAGGGTCAAGGGCT-3'; antisense: 5'-CCACACTCACAGTTTTCTCTT-3') in a total volume of 50 µL that contained 50 µM deoxynucleotide triphosphate, 1.5 mM MgCl₂, and 1 U Taq DNA polymerase; Takara Shuzo, Kyoto, Japan). Thirty-five cycles (denaturation at 94°C for 15 seconds, annealing at 58°C for 1 minute and 30 seconds, and polymerization at 72°C for 30 seconds) were performed using a GeneAmp PCR system 9600 (PerkinElmer, Oak Brook, Ill). After purification, each PCR product was digested with *Mbo*II (TOYOBO), electrophoresed on a 20% polyacrylamide gel, stained with ethidium bromide, and photographed. The *ALDH₂¹* allele produced fragments of 125 bp and 9 bp, and the *ALDH₂²* allele produced fragments of 134 bp.

The *CYP2E1* genotypes ascribed to the *Rsa*I site in the 5'-flanking region also were identified as RFLPs by PCR. Genomic DNA (100 ng) was subjected to PCR with each primer (sense, 5'-ATCCACAAGTGATTTGGCTG-3'; antisense, 5'-CTTCATACAGACCCTCTCC-3'). PCR was performed for 35 cycles under the following conditions: 1 minute at 95°C for denaturation, 1 minute at 55°C for primer annealing, and 1 minute at 72°C for primer extension. The 412-bp fragment was digested with *Rsa*I (TOYOBO). The products that were yielded were fragments with 360 bp and 50 bp for c1/c1; 360 bp, 50 bp, and 410 bp for c1/c2; and 410 bp for c2/c2 detected by electrophoretic analysis in 5% polyacrylamide gels.

Statistical Analysis

Patient characteristic (see Table 1) were compared with characteristic in the control group by using the Student *t* test or the chi-square test. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were obtained by unconditional logistic regression analy-

TABLE 1
Baseline Characteristics of Lung Cancer Cases and Controls

Characteristic	No. (%)		P for difference
	Cases (n = 505)	Controls (n = 256)	
Mean age SD, y	64.8 8.3	63.5 10.2	.06*
Sex			
Men	360 (71.3)	126 (49.2)	<.0001†
Women	145 (28.7)	130 (50.8)	
Smoking status			
Never	140 (27.7)	129 (50.4)	<.0001†
Past	97 (19.2)	64 (25)	
Current	268 (53.1)	63 (24.6)	
Smoking amounts, pack-years			
Past			
<27	35 (36.1)	32 (50)	.08†
27	62 (63.9)	32 (50)	
Current			
<40	71 (26.5)	30 (47.6)	.001†
40	197 (73.5)	33 (52.4)	
Alcohol drinking habit, times/wk			
Seldom	116 (23)	118 (46.1)	.0001†
2	43 (8.5)	42 (16.4)	
3-6	96 (19)	22 (8.6)	
Daily	250 (49.5)	74 (28.9)	
Alcohol amounts, g/day			
0	120 (23.8)	119 (46.5)	.0001†
<31.6	154 (30.5)	65 (25.4)	
31.6	231 (45.7)	72 (28.1)	

SD indicates standard deviation.

* Determined using the Student *t* test.

† Determined using the chi-square test.

sis. In our regression models, we adjusted ORs for potential confounding variables, including age, sex, smoking status (never, past, current) or amounts smoked (pack-years) and alcohol consumed (none, light, heavy). Because differences in the amount of alcohol consumed (ethanol, in gram per day) were very large, we divided those who drank into 3 categories: nondrinkers, light drinkers (< 31.6 g per day), and heavy drinkers (>31.6 g per day). The amount of tobacco smoke exposure was calculated as pack-years (usual amount per day/20 × overall duration [years] of use). Participants were considered current smokers if they smoked up to 1 year before the date of diagnosis in the case group or up to the date of the interview for the control group. The average amount of daily ethanol intake was calculated in grams. Calculation of this value was based on an average ethanol content of 4-volume% in beer, 15-volume% in Japanese sake (rice wine), 25-volume% in Japanese spirits (syochu), 12-volume% in wine, and 40-volume% in spirits. Drinking frequency was assessed as 5 categories: less than once a week, 1 or 2 days a week, 3 or 4 days a week, 5 or 6 days a

week, and daily. Categorical variables were compared with the chi-square test. ORs and 95% CIs were calculated by using logistic regression analysis adjusting for age, sex, smoking, and drinking. The Mantel extension test was used to evaluate linear trends across categories of alcohol consumption that were divided into 4 categories by quartiles for control. Resulting *P* values <.05 (2-tailed) were considered statistically significant. All statistical analyses were performed using the SAS statistical software package (SAS Institute Inc., Cary, NC).

RESULTS

In total 510 patients with lung cancer (cases) and 260 healthy controls participated in this study. Because of the lack of DNA samples or information on lifestyle, 9 participants were eliminated. Table 1 summarizes the baseline characteristics of selected variables for the lung cancer cases and controls. Age distribution was similar in both groups (mean, 64.8 years and 63.5 years, respectively); however, the cases were more likely than the controls to be men (71.3% and 49.2%), to be current smokers (53.1% and 24.6%) and heavy smokers, and to consume more alcohol. The proportions of those who consumed >31.6 g per day of ethanol and of daily drinkers were 45.7% and 49.5%, respectively, for cases and 28.1% and 28.9%, respectively, for controls. The median values from the control group for the 2 smoking amount categories were used as the cut-off values. The 3 categories of alcohol consumption were lifetime nondrinker, below the median intake, and above the median intake.

The frequency of *ADH₃*, *ALDH₂*, and *CYP2E1* genotypes and ORs among lung cancer cases and controls are presented in Table 2. After adjustment for age, sex, smoking amount, and amount of alcohol consumed, the ORs for individuals with the *ADH₃*, *ALDH₂*, and *CYP2E1* variant alleles, compared with individuals who were homozygous for the common allele, were 1.01, 0.73, and 0.93, respectively. Thus, there were no significant differences in the frequencies of any genotypes between cases and controls. The OR for carriers of the *CYP2E1* c2/c2 genotype, compared with the c1/c1 genotype, was 4.66 (*P* <.05). This genotype is not in Hardy-Weinberg equilibrium in the control population, the observed frequency is most likely an underestimate, and the finding of an association with lung cancer is most likely a false-positive result.

Without taking these genotypes into consideration, a direct association between alcohol consumption and lung cancer occurrence can be derived, as